Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2018

View Archived Issues

Early safety and efficacy data support use of MAGE-A4 SPEAR T cells for treatment of solid tumors

Targeting LILRB4 may augment immunotherapy in leukemia

First mouse model of Costello syndrome highlights role of altered metabolism in disease

A 20p11.2 deletion including FOXA2 causes hyperinsulinemic hypoglycemia

ZMYM2 -- a new candidate gene for congenital anomalies of the kidney and urinary tract

Acute kidney injury prevented in mice by prophylactic treatment with DNase I inhibitor

Obesity drives NASH, liver cancer via distinct mechanisms

Durable tumor responses reported for ODM-203 in phase I/II KIDES trial

Drugging "undruggable" zinc fingers

Clean antagonist antibody can control skin inflammation

BAY-1161909 in combination with paclitaxel demonstrates antitumor efficacy but trial terminated

Preliminary phase I results of ABBV-181 reported at ESMO

Limited antitumor efficacy and high rates of hypertension in breast cancer with lucitanib

AbbVie patents new BRD4 inhibitors

Zion Medical reports first clinical data for HIV drug Gammora

FDA approves pegfilgrastim biosimilar Udenyca

Cancer Research Technology identifies RET inhibitors

Phase III study of Venclexta with Gazyva in treatment-naive CLL meets primary endpoint

European Commission approves Symkevi in cystic fibrosis

FDA approves adalimumab biosimilar Hyrimoz

Interim phase I results reported for ISC-hpNSC cell therapy in Parkinson's disease patients

FDA issues complete response letter for oliceridine NDA

SanBio's phase II trial of SB-623 in traumatic brain injury meets primary endpoint

FDA approves Lorbrena for previously treated ALK-positive metastatic NSCLC

Leo Pharma opens phase Ib study of LEO-134310 in chronic plaque psoriasis

FDA approves Dsuvia for acute pain in healthcare settings

Recombinant Lassa-rabies virus vaccine LASSARAB protects guinea pigs from Lassa fever

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...